| Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. | |
| | |
MedLine Citation:
|
PMID: 15682068 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Seventy-two chronic myeloid leukemia patients were enrolled as part of a larger randomized trial at 3 centers between March 1996 and July 2001 to undergo either HLA-matched related allogeneic bone marrow (BM) or filgrastim (granulocyte colony-stimulating factor)-mobilized peripheral blood stem cell (PBSC) transplantation. Forty patients received BM, and 32 patients received PBSCs. There was no statistically significant difference in the incidence of acute or chronic graft-versus-host disease (GVHD), overall survival, disease-free survival, or non-relapse-related mortality between patients receiving BM or PBSC transplants. The cumulative incidence of grade II to IV acute GVHD was 49% in BM and 55% in PBSC recipients ( P = .48). The cumulative incidence of clinical extensive chronic GVHD was 50% in BM and 59% in PBSC recipients ( P = .46). Among 62 chronic phase chronic myeloid leukemia patients, there was no significant difference in overall survival (87% versus 81%; P = .59), disease-free survival (80% versus 81%; P = .61), or non-relapse-related mortality (13% versus 19%; P = .60) by cell source (BM versus PBSCs). Among chronic phase patients, however, there was a trend toward a higher cumulative incidence of relapse at 3 years in BM recipients (7% versus 0%; P = .10) and a higher cumulative incidence of chronic GVHD in PBSC recipients (59% versus 40%; P = .11). The trend toward a higher relapse incidence in BM recipients persisted with a longer follow-up. |
| | |
Authors:
|
Vivian G Oehler; Jerald P Radich; Barry Storer; Karl G Blume; Thomas Chauncey; Reginald Clift; David S Snyder; Stephen J Forman; Mary E D Flowers; Paul Martin; Katherine A Guthrie; Robert S Negrin; Frederick R Appelbaum; William Bensinger |
Related Documents
:
|
15181288 - Reconstructing immunity after allogeneic transplantation. 10517488 - Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic ste... 3552928 - The histological diagnosis of cutaneous graft versus host disease: relationship of skin... 15942098 - Successful reduced-intensity stem cell transplantation (rist) for a patient with malign... 14517198 - Renal transplantation in a case of acute intermittent porphyria. 8865248 - Effects of growth hormone on insulin-like growth factors and binding proteins before an... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Volume: 11 ISSN: 1083-8791 ISO Abbreviation: Biol. Blood Marrow Transplant. Publication Date: 2005 Feb |
Date Detail:
|
Created Date: 2005-01-31 Completed Date: 2005-06-15 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9600628 Medline TA: Biol Blood Marrow Transplant Country: United States |
Other Details:
|
Languages: eng Pagination: 85-92 Citation Subset: IM |
Affiliation:
|
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. voehler@u.washington.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bone Marrow Transplantation* Disease-Free Survival Graft vs Host Disease / mortality Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality, therapy* Peripheral Blood Stem Cell Transplantation* Recurrence Transplantation, Homologous |
| Grant Support | |
ID/Acronym/Agency:
|
CA-18029/CA/NCI NIH HHS; CA-49605/CA/NCI NIH HHS |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Visualization of coronary arteries using intravenous contrast agent and real-time 3-dimensional echo...
Next Document: High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous ...